Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis

AimThe aim of this study was to evaluate the diagnostic accuracy of 18F-fluorodeoxyglucose-PET (FDG-PET) and FDG-PET/computed tomography (CT) in the detection of recurrent or metastatic differentiated thyroid carcinoma (DTC) that was not identified by radioiodine whole-body scintigraphy (WBS). Patients and methodsA total of 25 studies (comprising 789 patients) that were published from January 1990 to September 2008 were reviewed. These studies evaluated the role of FDG-PET and FDG-PET/CT in the detection of recurrent or metastatic DTC that radioiodine WBS failed to detect. Systematic methods were used to identify, select, and evaluate the methodological quality of the studies and to summarize the overall findings of sensitivity and specificity. ResultsIn total, 17 studies with 571 patients who had recurrent or metastatic DTC and a radioiodine-negative whole-body scan were collected, and the overall patient-based sensitivity and specificity of FDG-PET were 0.835 [95% confidence interval (CI): 0.791–0.873] and 0.843 (95% CI: 0.791–0.886), respectively. Of these studies, six included lesion-based data, totaling 237 lesions, and the pooled lesion-based sensitivity and specificity were 0.916 (95% CI: 0.863–0.953) and 0.775 (95% CI: 0.660–0.865), respectively. The pooled sensitivity and specificity in the DTC patients who presented with elevated serum thyroglobulin and negative 131I scan were 0.885 (95% CI: 0.828–0.929) and 0.847 (95% CI: 0.715–0.934), respectively. In the six studies where the 165 patients were diagnosed by using FDG-PET/CT, pooled sensitivity and specificity were 0.935 (95% CI: 0.870–0.973) and 0.839 (95% CI: 0.723–0.920), respectively. ConclusionFDG-PET is especially effective in detecting patients with elevated thyroglobulin levels and normal radioiodine WBS; FDG-PET/CT is a more sensitive method in the follow-up of thyroid cancer recurrence or metastases, particularly in those with negative WBS.

[1]  Seong-Jang Kim,et al.  Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. , 2009, European journal of radiology.

[2]  N. Aygun.  Imaging of recurrent thyroid cancer. , 2008, Otolaryngologic clinics of North America.

[3]  Jun Zhao,et al.  Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature , 2008, Nuclear medicine communications.

[4]  J. Montilla-Soler,et al.  The Added Benefit of a Dedicated Neck F-18 FDG PET-CT Imaging Protocol in Patients With Suspected Recurrent Differentiated Thyroid Carcinoma , 2008, Clinical nuclear medicine.

[5]  A. Iagaru,et al.  F-18 FDG PET/CT in the Management of Thyroid Cancer , 2007, Clinical nuclear medicine.

[6]  G. Antoch,et al.  Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer , 2007, European Radiology.

[7]  C. Bodet-Milin,et al.  Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. , 2007, Surgery.

[8]  H. Gallowitsch,et al.  Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Badreddine Bencherif,et al.  18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  I. Virgolini,et al.  99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  E. Wardelmann,et al.  Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  D. Ng,et al.  Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. , 2005, Singapore medical journal.

[13]  T. Saga,et al.  Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  R. Moncayo,et al.  99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  T. Higuchi,et al.  PET in the follow-up of differentiated thyroid cancer. , 2003, The British journal of radiology.

[16]  A. Alessi,et al.  FDG-PET in Thyroid Cancer , 2003, Tumori.

[17]  S. Zwas,et al.  The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma , 2003, Nuclear medicine communications.

[18]  R. Delgado-Bolton,et al.  Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  E. Kresnik,et al.  18F-FDG-PET in the follow-up of thyroid cancer. , 2003, Acta medica Austriaca.

[20]  C. Snyderman,et al.  Combined Positron Emission Tomography/Computed Tomography Imaging of Recurrent Thyroid Cancer , 2003, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[21]  C. Kao,et al.  F18‐Fluorodeoxyglucose Positron Emission Tomography in Detecting Metastatic Papillary Thyroid Carcinoma with Elevated Human Serum Thyroglobulin Levels But Negative I‐131 Whole Body Scan , 2003, Endocrine research.

[22]  R. Görges,et al.  Preoperative Diagnostic Value of [18F] Fluorodeoxyglucose Positron Emission Tomography in Patients With Radioiodine-Negative Recurrent Well-Differentiated Thyroid Carcinoma , 2001, Annals of surgery.

[23]  P. Merlet,et al.  Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  D. Lee,et al.  F‐18‐fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I‐131 scan–negative thyroid carcinoma patients with local recurrence in cervical lymph nodes , 2001, Head & neck.

[25]  R. Görges,et al.  Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. , 2000, Surgery.

[26]  S S Gambhir,et al.  A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  J. Llamas-Elvira,et al.  Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. , 2000, American journal of surgery.

[28]  G. Coates,et al.  FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[30]  P. V. van Rijk,et al.  Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results , 1999, European Journal of Nuclear Medicine.

[31]  V. Lazar,et al.  Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. , 1999, The Journal of clinical endocrinology and metabolism.

[32]  D. Lee,et al.  Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  O. Schober,et al.  Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans , 1998, Langenbeck's Archives of Surgery.

[34]  N. Sadato,et al.  Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. , 1998, Journal of Nuclear Medicine.

[35]  M. Dietlein,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.

[36]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  H. Biersack,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer , 1996, European Journal of Nuclear Medicine.

[38]  K. Ain,et al.  Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. , 1995, The Journal of clinical endocrinology and metabolism.

[39]  H. Joensuu,et al.  Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  P. Grigsby,et al.  Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer , 2007, Annals of Surgical Oncology.

[41]  R. Buchert,et al.  Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  Grü Nwald.  FDG PET in Thyroid Cancer: Thyroxine or Not? , 2000 .

[43]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.